Beta bionics announces closing of $234.6 million initial public offering and full exercise of underwriters' option to purchase additional shares

Irvine, calif., jan. 31, 2025 (globe newswire) -- beta bionics, inc. (nasdaq: bbnx), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of its upsized initial public offering of 13,800,000 shares of common stock, including the full exercise of the underwriters' option to purchase 1,800,000 additional shares, consisting of 475,000 additional shares from beta bionics and 1,325,000 shares from the selling stockholders named in the prospectus, at a price to the public of $17.00 per share. the gross proceeds to beta bionics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by beta bionics, were approximately $212.1 million. beta bionics did not receive any proceeds from any sale of shares by the selling stockholders. the shares began trading on the nasdaq global market on january 30, 2025 under the ticker symbol “bbnx.”
BBNX Ratings Summary
BBNX Quant Ranking